Pfizer, Novartis Agree UK Price Cuts for New Breast Cancer Drugs Pfizer, Novartis Agree UK Price Cuts for New Breast Cancer Drugs

Pfizer and Novartis have agreed price cuts for their rival breast cancer drugs Ibrance (palbociclib) and Kisqali (ribociclib) to ensure they can be used routinely within Britain ' s state-funded health service.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news